Table 1.
Demographics of patients included who underwent surgery for Bethesda III or IV indeterminate thyroid nodules with ThyroSeq v2 testing, by institution. B III, Bethesda III; B IV, Bethesda IV; MSKCC, Memorial Sloan-Kettering Cancer Center; MCC, Moffitt Cancer Center; CSMC, Cedars-Sinai Medical Center; MSHS, Mount Sinai Health System.
| MSKCC | MCC | CSMC | MSHS | Combined | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patients (n) | 97 | 97 | 13 | 59 | 266 | |||||
| Female, n (%) | 69 (71) | 77 (79) | 10 (77) | 44 (75) | 200 (75) | |||||
| Age, mean (SD) |
51 (15) | 56 (11) | 42 (17) | 52 (15) | 53 (14) | |||||
| Nodules (n) | 98 | 102 | 13 | 60 | 273 | |||||
| B III | B IV | B III | B IV | B III | B IV | B III | B IV | B III | B IV | |
| Nodules, n (%) |
55 (56) |
43 (44) |
52 (51) |
50 (49) |
9 (69) |
4 (31) |
45 (75) |
15 (25) |
161 (59) |
112 (41) |
| Nodule size (cm), mean (SD) |
2.1 (1.3) |
2.9 (1.3) |
2.6 (1.6) |
3.0 (1.5) |
2.8 (1.1) |
2.2 (1.0) |
2.5 (1.6) |
3.5 (2.1) |
2.4 (1.5) |
3.0 (1.5) |
| ThyroSeq v2 positive, n (%) |
41 (75) |
33 (77) |
16 (31) |
17 (34) |
8 (89) |
3 (75) |
30 (67) |
7 (47) |
95 (59) |
60 (54) |
| Malignancy rate, n (%) |
19 (35) |
36 (84) |
5 (10) |
10 (20) |
0 | 3 (75) |
6 (13) |
3 (20) |
30 (19) |
52 (46) |